Tolerx, Inc. was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company was focused on discovering and developing new therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases after a short course of therapy. Targeted diseases include type 1 diabetes, rheumatoid arthritis, Inflammatory bowel disease (IBD), cancer, chronic and viral diseases. In 2008, Tolerx was named one of Fierce Biotech’s Fierce 15. In October 2011, Tolerx was shut down due to an unsuccessful Phase III trial in patients recently diagnosed with Type 1 diabetes.
| Property |
Value |
| dbo:abstract |
Tolerx, Inc. was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company was focused on discovering and developing new therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases after a short course of therapy. Targeted diseases include type 1 diabetes, rheumatoid arthritis, Inflammatory bowel disease (IBD), cancer, chronic and viral diseases. In 2008, Tolerx was named one of Fierce Biotech’s Fierce 15. In October 2011, Tolerx was shut down due to an unsuccessful Phase III trial in patients recently diagnosed with Type 1 diabetes. (en) |
| dbo:foundingYear |
2000-01-01 (xsd:gYear) |
| dbo:industry |
dbr:Biotechnology |
| dbo:location |
dbr:Cambridge,_Massachusetts |
| dbo:thumbnail |
wiki-commons:Special:FilePath/TolerxLogo.jpg?width=300 |
| dbo:wikiPageExternalLink |
http://www.tolerx.com/ |
| dbo:wikiPageID |
22397545 (xsd:integer) |
| dbo:wikiPageLength |
6635 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1106781719 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cambridge,_Massachusetts dbr:Cancer dbr:Monocyte dbr:Rheumatoid_arthritis dbr:Virus_disease dbc:Biotechnology_companies_of_the_United_States dbr:Genentech dbr:Monoclonal_antibodies dbr:Multiple_sclerosis dbr:Dendritic_cell dbr:Diabetes_mellitus_type_1 dbc:Companies_based_in_Cambridge,_Massachusetts dbc:Pharmaceutical_companies_disestablished_in_2011 dbc:Defunct_companies_based_in_Massachusetts dbr:Food_and_Drug_Administration_(United_States) dbr:Otelixizumab dbc:Privately_held_companies_based_in_Massachusetts dbr:Biotechnology dbr:Systemic_lupus_erythematosus dbc:Pharmaceutical_companies_established_in_2000 dbr:CD4 dbr:Inflammatory_bowel_disease dbr:Chronic_(medicine) dbr:Lupus_erythematosus dbr:GITR dbr:Glaxo_SmithKline |
| dbp:foundation |
2000 (xsd:integer) |
| dbp:homepage |
http://www.tolerx.com/ |
| dbp:industry |
dbr:Biotechnology |
| dbp:location |
dbr:Cambridge,_Massachusetts |
| dbp:logo |
TolerxLogo.jpg (en) |
| dbp:logoSize |
200 (xsd:integer) |
| dbp:name |
Tolerx, Inc. (en) |
| dbp:type |
Private (en) |
| dbp:wikiPageUsesTemplate |
dbt:Citation_needed dbt:Infobox_company dbt:Reflist |
| dcterms:subject |
dbc:Biotechnology_companies_of_the_United_States dbc:Companies_based_in_Cambridge,_Massachusetts dbc:Pharmaceutical_companies_disestablished_in_2011 dbc:Defunct_companies_based_in_Massachusetts dbc:Privately_held_companies_based_in_Massachusetts dbc:Pharmaceutical_companies_established_in_2000 |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatBiotechnologyCompaniesOfTheUnitedStates yago:WikicatCompaniesBasedInCambridge,Massachusetts yago:WikicatCompaniesDisestablishedIn2011 yago:WikicatCompaniesEstablishedIn2000 yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 yago:WikicatDefunctCompaniesBasedInMassachusetts yago:WikicatPrivatelyHeldCompaniesBasedInMassachusetts |
| rdfs:comment |
Tolerx, Inc. was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company was focused on discovering and developing new therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases after a short course of therapy. Targeted diseases include type 1 diabetes, rheumatoid arthritis, Inflammatory bowel disease (IBD), cancer, chronic and viral diseases. In 2008, Tolerx was named one of Fierce Biotech’s Fierce 15. In October 2011, Tolerx was shut down due to an unsuccessful Phase III trial in patients recently diagnosed with Type 1 diabetes. (en) |
| rdfs:label |
Tolerx (en) |
| owl:sameAs |
freebase:Tolerx yago-res:Tolerx wikidata:Tolerx https://global.dbpedia.org/id/4wSDL |
| prov:wasDerivedFrom |
wikipedia-en:Tolerx?oldid=1106781719&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/TolerxLogo.jpg |
| foaf:homepage |
http://www.tolerx.com/ |
| foaf:isPrimaryTopicOf |
wikipedia-en:Tolerx |
| foaf:name |
Tolerx, Inc. (en) |
| is dbo:wikiPageRedirects of |
dbr:Tolerx,_Inc. |
| is dbo:wikiPageWikiLink of |
dbr:TRX1 dbr:Tolerx,_Inc. |
| is foaf:primaryTopic of |
wikipedia-en:Tolerx |
